ENTA - Enanta Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Enanta Pharmaceuticals, Inc.

500 Arsenal Street
Watertown, MA 02472
United States

Full Time Employees89

Key Executives

NameTitlePayExercisedYear Born
Dr. Jay R. LulyPres, CEO & Director867.84kN/A1956
Mr. Paul J. Mellett Jr.Sr. VP-Fin. & Admin., CFO and Principal Accounting Officer513.18kN/A1955
Dr. Yat Sun OrSr. VP-R&D and Chief Scientific Officer564.64kN/A1952
Dr. Nathalie AddaSr. VP & Chief Medical OfficerN/AN/A1966
Mr. Nathaniel S. Gardiner J.D.Sr. VP, Gen. Counsel & Sec.N/AN/A1954
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Enanta Pharmaceuticals, Inc., a biotechnology company, focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company's research and development focuses on disease targets: hepatitis B virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and respiratory syncytial virus. It has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.

Corporate Governance

Enanta Pharmaceuticals, Inc.’s ISS Governance QualityScore as of March 1, 2018 is 5. The pillar scores are Audit: 2; Board: 4; Shareholder Rights: 8; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.